Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Robertson, A. J.
Right arrow Articles by Morris, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robertson, A. J.
Right arrow Articles by Morris, P. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 1865-1868
© 2000 European Renal Association-European Dialysis and Transplant Association


Brief Report

Low dose aspirin as prophylaxis against renal-vein thrombosis in renal-transplant recipients

Amanda J. Robertson, Vinod Nargund, Derek W. R. Gray and Peter J. Morris

Nuffield Department of Surgery, Oxford Transplant Centre, Churchill Hospital, Headington, Oxford, UK

Background. Renal-vein thrombosis (RVT) is an infrequent event that accounts for a high proportion of early renal allograft losses, since graft failure secondary to acute irreversible rejection is now relatively rare. The cause of RVT may be related to technical problems, clotting disorders, diabetes, or cyclosporin, but is often difficult to define.

Methods. This retrospective study was performed to examine the influence of aspirin on the incidence of RVT in cadaveric and living-related renal transplant recipients receiving cyclosporin-based triple immunosuppression. The Oxford Transplant Centre database was used to identify all early (<30 day) non-immunological graft failures and case histories were examined for clinical and pathological evidence of RVT. In July 1991, aspirin (75 mg o.d. starting immediately before and continuing for 1 month post-transplant) was introduced as routine prophylaxis against RVT. Prior to this, aspirin prophylaxis was not used.

Results. In the 6-year period from July 1985 to June 1991, there were 27 cases of RVT in 475 transplants (5.6%). In the subsequent 6-year period, there were six cases of RVT in 480 transplants (1.2%) (P<0.01).

Conclusion. Although not abolished, this indicates a significant reduction in the incidence of RVT with the addition of low-dose aspirin.

Keywords: low-dose aspirin; prophylaxis; renal-transplant recipients; renal-vein thrombosis; retrospective study

Correspondence and offprint requests to: Mr D. W. R. Gray, Oxford Transplant Centre, Churchill Hospital, Oxford OX3 7LJ, UK.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
C. Ponticelli, M. Moia, and G. Montagnino
Renal allograft thrombosis
Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1388 - 1393.
[Full Text] [PDF]


Home page
J Ultrasound MedHome page
J. Gao, A. Ng, G. Shih, M. Goldstein, S. Kapur, J. Wang, and R. J. Min
Intrarenal Color Duplex Ultrasonography: A Window to Vascular Complications of Renal Transplants
J. Ultrasound Med., October 1, 2007; 26(10): 1403 - 1418.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
A S. Mathis, N. Dave, N. K Shah, and G. S Friedman
Bleeding and Thrombosis in High-Risk Renal Transplantation Candidates Using Heparin
Ann. Pharmacother., April 1, 2004; 38(4): 537 - 543.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.